EASD 2019 — Ultra rapid lispro features faster absorption in T1D


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Ultra rapid lispro (URLi) was faster in its absorption, was associated with the lowest postprandial glucose (PPG), and more closely matched a normal physiological profile of patients without diabetes compared with insulin lispro (IL), insulin aspart (IA), and fast-acting insulin aspart (FA) in patients with type 1 diabetes (T1D).

Why this matters

  • Many insulins are not fast enough to match the rate of carbohydrate absorption.

Study design

  • Patients with T1D (n=68) and healthy control patients (n=12) were enrolled.
  • Prior to the start of a 5-hour liquid meal test consisting of approximately 100 g carbohydrate, participants were randomly assigned to receive a single subcutaneous dose of either URLi, IL, IA, or FA.
  • Healthy control patients received the same liquid meal but no insulin.
  • Funding: Eli Lilly and Company.

Key results

  • URLi featured the fastest insulin absorption at 13 minutes compared with 19 minutes using FA, 25 minutes with IL, and 27 minutes with IA (P<.05 urli vs other insulins>
  • A greater percentage reduction in late insulin exposure (2-7 hours) was observed with URLi vs FA (37%), URLi vs IL (30%), and URLi vs IA (45%) (all P<.001>
  • At 1 hour following the meal, URLi reduced PPG excursions by 1.4 mmol/L vs IL (P<.0001 mmol vs ia and fa>
  • The PPG profile of URLi also more closely matched that observed in healthy control patients in the first 2 hours after the meal test. 

Limitations

  • Small sample size.